CytomX Therapeutics (CTMX) FCF Margin (2014 - 2026)

CytomX Therapeutics has reported FCF Margin for 13 years, with the latest figure at 249.06% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin fell 20750.0% year-over-year to 249.06%; the trailing twelve-month figure through Mar 2026 stood at 225.63% (down 17057.0% YoY), and the FY2025 full-year result was 99.48%, down 3704.0% from the prior year.
• FCF Margin for Q1 2026 stood at 249.06%, up from 3536.05% in the prior quarter.
• The five-year high for FCF Margin was 39.58% in Q1 2023, with the low at 3536.05% in Q4 2025.
• Historically, FCF Margin has averaged 334.31% across 5 years, with a median of 83.55% in 2023.
• Annual changes were most pronounced in 2023 — FCF Margin jumped 50472 bps — and 2025, when it slumped 348437 bps.
• CytomX Therapeutics' FCF Margin stood at 0.79% in 2022, then tumbled by 10674 bps to 83.55% in 2023, then surged by 38 bps to 51.68% in 2024, then tumbled by 6742 bps to 3536.05% in 2025, then soared by 93 bps to 249.06% in 2026.
• The last three FCF Margin figures came in at 249.06% (Q1 2026), 3536.05% (Q4 2025), and 258.61% (Q3 2025), per Business Quant data.